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Integration of acquired immunity into microbial risk assessment for illness incidence is of
no doubt essential for the study of susceptibility to illness. In this study, a probabilistic
model was set up as dose response for infection and a mathematical derivation was carried
out by integrating immunity to obtain probability of illness models. Temporary acquire
immunity from epidemiology studies which includes six different Norovirus transmission
scenarios such as symptomatic individuals infectious, pre- and post-symptomatic infec-
tiousness (low and high), innate genetic resistance, genogroup 2 type 4 and those with no
immune boosting by asymptomatic infection were evaluated.
Simulated results on illness inﬂation factor as a function of dose and exposure indicated
that high frequency exposures had immense immunity build up even at high dose levels;
hence minimized the probability of illness. Using Norovirus transmission dynamics data,
results showed, and immunity included models had a reduction of 2e6 logs of magnitude
difference in disease burden for both population and individual probable illness incidence.
Additionally, the magnitude order of illness for each dose response remained largely the
same for all transmission scenarios; symptomatic infectiousness and no immune boosting
after asymptomatic infectiousness also remained the same throughout. With integration of
epidemiological data on acquired immunity into the risk assessment, more realistic results
were achieved signifying an overestimation of probable risk of illness when epidemio-
logical immunity data are not included. This ﬁnding supported the call for rigoroustics, Faculty of Physical and Computational Science, College of Science, Kwame Nkrumah University of
gh (E.d.-G.J. Owusu-Ansah).
unications Co., Ltd.
ting by Elsevier B.V. on behalf of KeAi Communications Co., Ltd. This is an open access article under the
icenses/by-nc-nd/4.0/).
E.d.-G.J. Owusu-Ansah et al. / Infectious Disease Modelling 4 (2019) 99e114100integration of temporary acquired immunity in dose-response in all microbial risk
assessments.
© 2019 The Authors. Production and hosting by Elsevier B.V. on behalf of KeAi
Communications Co., Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The adoption of quantitative approach in modeling epidemiological risk over the years has gained interest in the ﬁeld of
disease modeling and epidemiology. This approach has led to the use of adopting techniques in characterizing uncertainty of
input parameters with cumulative density functions, probability density functions and probability mass functions.
Mathematical epidemiology of diseases with compartmental models have covered almost all forms of diseases empha-
sizing the different transmission approaches with intervention inclusion models. Yet, only a few studies have been
concentrating on using the same approach for the pathogen of interest causing such diseases. The transition of infection to
illness for pathogens has received less attention in quantitative risk modeling (Havelaar & Swart, 2014). This is as a result of
lack of integration of epidemiological studies approach in quantitative risk assessment, such as a quantitative model of a
susceptible individual suffering from pathogenic attack, transiting from partial recovery to become susceptible again (Swart,
Tomasi, Kretzschmar, Havelaar, & Diekmann, 2012).
In the light of the above, this study attempts to apply the integration of mathematical epidemiological method into
quantitative risk assessment for modeling probability of illness by incorporating acquired immune function to predict the
expected probability of illness for exposure to norovirus, a major gastrointestinal pathogenic virus.
2. Literature and review of mathematical probability of infection
Developing amathematical dose response relationship is the same as establishing the relations between level of pathogen,
exposure and themeasure of likelihood occurrence of adverse effects (Haas, Rose,&Gerba, 2014, pp. 267e321). Furumoto and
Mickey (1967) in estimating the consequences of exposure to different level of pathogens noted that, the process of infection
is considered to be two sequential sub processes, namely;
i. One or more organism(s) or virus particles ingested is (are) capable of causing diseases
ii. An ingested organism/virus particle can become inactivated to multiply to cause infection/disease by host susceptible
responses, and only a fraction of the ingested organisms reaches a site where infection can begin by breaking all barriers
within the body immune system.
Hence, ingestion precisely j organism from exposure with a mean dose d is expressed as
P1ðjjdÞ (1)Therefore, probability of k surviving pathogen particles to initiate an infection process is also express as
P2ðkjjÞ (2)Assuming independency for the two processes, the probability of k organisms surviving to initiate infection by breaking all
defense mechanism within the body is given by the independent event
PðkÞ ¼
X∞
j¼1
P1ðjjdÞP2ðkjjÞ (3)The least number of organisms (kmin) surviving to initiate an infection leads to a probability of infection
Pinf ðdÞ ¼
X∞
k¼kmin
X
j¼k
P1ðjjdÞP2ðkjjÞ (4)
Where (kmin) is not the minimal infection dose or threshold needed to be reached to cause an infection.
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Characterizing the distribution of organisms between each dose as random and assuming independency for each ingested
organism has an identical survival probability1 r and kmin ¼ 1 (thus for a single hit assumption). Hence from Poisson dis-
tribution of organisms with the use of equation (1) leads to
P1ðjjdÞ ¼ d
j
j!
ed (5)From equation (5) incorporating equation (2), survival means of organisms to cause an infection is modeled with binomial
distribution leading to
P2ðkjjÞ ¼ j!
k!ðjjkÞ!ð1 rÞ
jk (6)Hence, substituting equations (5) and (6) into equation (4) and accounting for infectivity of the virus ‘r’ leads to the
expression below
Pinf ðdÞ ¼
X∞
k¼kmin
X
j¼k
"
dj
j!
ed
#
j!
k!ðjjkÞ!ð1 rÞ
jk

X∞ ðdrÞkedrX∞ ½dð1 rÞ½jkeðd½1rÞ¼
k¼kmin k! j¼k ðj kÞ!
(7)
X∞ ðdrÞkedr
But
k¼kmin k!
¼ 1 ; hence
" Xkmin1 ðdrÞkedr#
Pinf ðdÞ ¼ 1
k¼0 k!
(8)With the earlier single hit assumption (thus one organism survived is capable to cause an infection) kmin ¼ 1 yields
Pinf ðdÞ ¼ 1 erd (9)2.2. Derivation of the Beta-Poisson dose response model
Replacing equation (6) with a mixture distribution with respect to the parameter r to account for variability in the
infectivity interaction probability yields equation (10)
P2ðkjjÞ ¼
Z1
0

j!
k!ðj kÞ!ð1 rÞ
jkrk

f ðrÞdr (10)Equation (6) through various mathematical formulation yields equation (10), therefore, a mixture distribution application
on equation (9) for a variation in the dose to dose in the poison distribution yields
Pinf ðdÞ ¼
Z1
0
h
1 erd
i
f ðrÞdr (11)
Z1 Z1
¼
0
f ðrÞdr 
0
erdf ðrÞdr1 This is a probability that an organism survives all barriers of defense mechanism and initiate and infectious focus within cell.
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Z1
0
erdf ðrÞdr (12)Let the variation on dose to dose assume the beta distribution and for the purposes of a great deal of ﬂexibility due to its
suitable applications (Haas et al., 2014, pp. 267e321), hence incorporating into equation (12) yields
Pinf ðdÞ ¼ 1
Z1
0

Gðwþ bÞ
GðwÞGðbÞr
w1ð1 rÞb1

erddr (13)The integral can best be expressed as conﬂuent hyper-geometric function of the ﬁrst kind written as a series expansion
1F1ðw;wþ b;dÞ ¼ 1þ
Gðwþ bÞ
GðwÞ
X∞
j¼1
Gðwþ jÞ
Gðwþ bþ jÞ
ðdÞj
j!
(14)Therefore, the exact solution of the beta ePoisson model can be written as
Pinf ðdÞ ¼
Gðwþ bÞ
GðwÞ
X∞
j¼1
"
Gðwþ jÞ
Gðwþ bþ jÞ
ð1Þj1ðdÞj
j!
#
(15)Teunis et al. (2008) noted that, the ingestion of a virion is based on whether it is aggregated or disaggregated, as virion
particles may or may not be aggregated depending on the circumstances of the environment. Hence the conﬂuent hyper-
geometric function yields:
Pinf ðdÞ ¼ 1 1F1ðw;wþ b;dÞ (16)Furumoto and Mickey (1967)derived the following expression approximation to equation (14) based on the certain valid
parameter values, thus when b  1 and w<b the simple relation holds.
Pinf ðdÞ ¼ 1

1þ d
b
a
(17)Furumoto and Mickey (1967) noted, any changes in b cause the Beta Poisson dose response relation to be shifted along the
dose axis without changing shape. However, the hyper-geometric relation cannot be scaled due to its non-scalability of the
beta distribution for r (Teunis, 2005).
2.3. Beta Poisson to fractional Poisson model
Accounts from Teunis et al. (2008) noted, in applying equation (16) for quantiﬁcation of probability of illness, human
ingestion of virus particles found to share a common probability ðrÞ independently capable of initiating infection in subjects,
though it is admitted some subjects may have very small values of r near zero and vice versa. Therefore, the aggregated
norovirus infection probability is a beta function parameters described as
Pinfðd;w; bÞ ¼ 1 2F1ðw; dð1 aÞ=a;wþ b;a=ð1 aÞÞ (18)Where w , b are shape parameters of beta distribution, a is the particle size, hence mean aggregate size mðaÞ is of the form
mðaÞ ¼ a=ðð1 aÞlnð1 aÞÞ (19)The result in probability of subjects receiving exactly zero aggregate is

e
d=mðaÞ

and those with one or more aggregate is
1

e
d=mðaÞ

.
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Messner, Berger, and Nappier (2014) noted that, variation in probability of infection across a susceptible population is
described with a mixture distribution by the use of beta parameters, hence describing individual probability of infectionwith
Bernoulli distribution as a mixture model.
r  BernoulliðpÞTherefore, individual probability of infection is exactly 1 with probability p and exactly 0 with probability 1 p, and cannot
assume any value within the interval 0-1with a parameter derivation of j, this incorporation led to probability of infection
described by as:
Pinfðdose;jÞ ¼ j

1 ed=mðaÞ

(20)3.1. Exposure scenarios
Given that, illness is independent of its previous events, then the probability of illness can be described with a Bernoulli
distributionwith ﬁxed exposure (E) for a period of time in a known population of size N (Messner et al., 2014). Therefore, the
total sum of illness could be derived as a “Naïve Model” (Hass et al., 1999) described as Pill ¼ PilljinfPinf , hence the derivation
is given as
I ¼
XN
k¼1
XE
j¼1
Pilljinf

dj;k

Pinf

dj;k

(21)For cases of independency of infection to exposure, Pilljinf ¼ 4, the conditional probability could be described for a single
exposure as Pill ¼ fPinfðdÞ. This resulting as a constant average dose, hence total number of illness for individual exposure is
I ¼ NE4PinfðdÞ (22)3.1. Acquired immunity from exposure
An individual may move from a disease susceptible compartment to full protection, partial protection and to total waning
off of protection to become susceptible again. The acquired immunity for frequent exposure in a Susceptible (S), Full pro-
tection (P) and Partial protection (Q) (SPQ compartmental model) has the parameters shown in Table 1.
The deterministic ﬁrst order differential equation for SPQ model can be described as follows;
f1 ¼
dS
da
¼ gQ  lS
f2 ¼
dP
da
¼ lðQ þ SÞ  aP
f3 ¼
dQ
da
¼ aP  ðgþ lÞQ
9>>>>>=
>>>>;
(23)
where, all parameters are positive, thus S(0), P(0) and Q(0)>0. The Jacobian is represented as;Table 1
Description of Parameters used in the Model.
Symbols Description
a Loss of full immunity
g Loss of partial immunity
l Force of infection
p Proportion of the susceptible involving of illness
S Susceptible population
P Fully protected after infection
Q Partial protection
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daj
¼
2
666666664
df1
dS
df1
dP
df1
dQ
df2
dS
df2
dP
df2
dQ
df3
dS
df3
dP
df3
dQ
3
777777775
¼
0
@l 0 gl a l
0 a ðlþ gÞ
1
A (24)For detðJ XIÞ ¼ 0, the resulting characteristic equation is
J  XI ¼
0
@l X 0 gl a X l
0 a ðlþ gÞ  X
1
A (25)
X3 þ lX2 þ gX2 þ aX2 þ alX þ agX þ lX2 þ l2X þ lgX ¼ 0X3 þ lX2 þ gX2 þ aX2 þ lX2 þ alX þ agX þ l2X þ lgX ¼ 0X3 þ ð2lþ gþ aÞX2 þ

alþ agþ l2 þ lg

X ¼ 0X
h
X2 þ ð2lþ gþ aÞX þ

alþ agþ l2 þ lg
i
¼ 0 (26)Therefore, the eigenvalues of the characteristics equation are
X1 ¼ 0;X2 ¼ ðaþ lÞ;X3 ¼ ðlþ gÞ (27)
and the corresponding eigenvectors are: ðag;lðlþ gÞ;alÞ; ð g; ðg aÞ;aÞ; ð1;0;  1Þ.
According to Swart et al. (2012) if R is assigned to be the average number of individual transition Susceptible compartment
to Fully protection compartment before ultimately dying of natural cause, assuming no individual dies from illness from
exposure, such a transition can be deﬁned as R ¼ l
Z ∞
0
sðaÞFðaÞda, where s(a) is the probability of individual susceptibility at
age ‘a’, and F(a) is the individual probability to survive until age ‘a’. Therefore, the full and partial waning of immunity is given
as;
d
da
0
@ sp
q
1
A ¼
0
@l 0 gl a l
0 a ðlþ gÞ
1
A
0
@ sp
q
1
A (28)
sð0Þ ¼ 1; pð0Þ ¼ 0; qð0Þ ¼ 0The general solution using the eigenvalues and eigenvectors of equation are0
@ sðaÞpðaÞ
qðaÞ
1
A ¼ C1
0
@ aglðgþ lÞ
al
1
A þC2
0
@ gðg aÞ
a
1
Aexp½aðaþ lÞþC3
0
@ 10
1
1
Aexp½aðgþ lÞ
0
1
1 0
ag
1 0 g 1 0 1 1@0
0
A ¼ C1@ lðgþ lÞ
al
A þC2@ ðg aÞ
a
AþC3@ 0
1
A (29)
1 ¼ agC1  gC2þC3
0 ¼ lðgþ lÞC1 þ ðg aÞC2
0 ¼ alC1 þ aC2  C3
1 l al
C1 ¼ ðaþ lÞðgþ lÞ;C2 ¼ ða gÞðaþ lÞ;C3 ¼ ða gÞðgþ lÞ
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BB@
sðaÞ
pðaÞ
qðaÞ
1
CCA ¼ 1ðaþ lÞðgþ lÞ
0
BB@
ag
lðgþ lÞ
al
1
CCA
þ 1ða gÞðaþ lÞ
0
BB@
g
ðg aÞ
a
1
CCAexp½aðaþ lÞ
þ alða gÞðgþ lÞ
0
BB@
1
0
1
1
CCAexp½aðgþ lÞ
9>>>>>>>>=
>>>>>>>;
(30)The relevant solution for quantiﬁcation of expected number of transition into the susceptible compartment after waning of
immunity is given as;
sðaÞ ¼ alðaþ lÞexp½aðgþ lÞ þ agða gÞ  glðgþ lÞexp½aðaþ lÞða gÞðaþ lÞðgþ lÞ (31)

Let the probability to survive until age ‘a’ be described by a survival function FðaÞ ¼ 1; 0  a  A0; a>A , where A is the life
expectancy of the population under study, consequently, the total transition from S to P of an individual is
R ¼ al
2
ða gÞðgþ lÞ2
½1 exp½Aðgþ lÞ
 gl
2
ða gÞðaþ lÞ2
½1 exp½Aðaþ lÞ
þ algAðaþ lÞðgþ lÞ ½1 exp½Aðgþ lÞ
9>>>>>>=
>>>>>>;
(32)
R alg
lim
A/∞A
¼ ðaþ lÞðgþ lÞ (33)Hence
R ¼ lA agðaþ lÞðgþ lÞ≡lAt (34)Henceforth, deﬁning force of infection as l ¼ EPinfðdÞ where E is the total number of days of exposure to a pathogen, and
whereas the factor t is obtained from binomial model of exposure as described in Messner et al. (2014).
t ¼ agðaþ gÞðgþ lÞ
agt ¼ ½aþ EPinfðdÞ½gþ EPinfðdÞ (35)FromMessner et al. (2014), characterizing the impact of immunity by the inﬂation factor scaling the naïve model leads to
the immunity model given as
I ¼ tNE4Pinf ðdÞ (36)As dose d/∞ (Higher dose level), Pinf ðdÞz1, Hence the immunity model in such a scenario is described as
I ¼ tNE4 (37)
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Modeling the hazard function of illness, let 0  t <L, where L is the entire period of infection for time t, therefore, the
hazard function HðtÞ for probability of illness given infection from equation (12) can now be written as;
HðtÞ ¼ Pðilljinf : uÞ ¼ 1 exp
2
4 Z
t
0
hðtÞdt
3
5; 0  t <L (38)
d d
hðtÞ ¼ 
dt
ln½1 FðtÞ ¼ 
dt
ln SðtÞ
Zt
HðtÞ¼def
0
hðuÞdu; t >0
¼ ln½1 FðtÞ
¼ ln SðtÞ
SðtÞ ¼ expðHðtÞÞ
f ðtÞ ¼ hðtÞexpðHðtÞÞ (39)Scaling the infection period leads to an integral of the hazard function Hðt=LÞ over the period of infection and assuming an
exponential model for the survival function, if the scale factor is h, Messner et al. (2014) shown such equation as
Pðilljinf ;LÞ ¼ 1 expðhLÞ (40)Adoption of Gamma distribution for the unknown infection duration L to account for individual heterogeneity in resis-
tance and persistence of host to colonization of infection leads to
gðL;u; dÞ ¼ d
u
GðuÞL
u1 exp
L
d

Z∞ " u  #
PðilljinfÞ ¼
r¼0
½1 expðhLÞ d
GðuÞL
u1 exp
L
d
dL
Z∞ " u  # Z∞   
¼
r¼0
d
GðuÞL
u1 exp
L
d
dL
r¼0
Lu1 exp
L
d
expðhLÞdL
u Z∞    9>
¼ 1 d
GðuÞ
r¼0
Lu1 exp
Lð1þ hÞ
d
dL
PðilljinfÞ ¼ 1 ð1þ hdÞu
>>=
>>>;
(41)
Where u and hd are the shape and scale parameters of an underlying Gamma distribution for duration of infection describing
the heterogeneity in response of subjects (Messner et al., 2014; Teunis et al. 1999, 2008).
Pillj^ınf ¼ 1 ð1þ hdÞr (42)Therefore, the dose model is given as
I ¼ NE

1 ð1þ hdÞr

Pinf ðdÞ (43)3.3. Combined model with immunity and dose dependence
The dose-immunity model combines the effects of acquired immunity and dose-dependent conditional probability of
illness (equation (37) and equation (43)) (Messner et al., 2014) as
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
1 ð1þ hdÞr

Pinf ðdÞ (44)4. Data assimilation, results and discussions
4.1. Probabilistic simulation and data assimilation
Modeling the acquired temporary immune probability of illness requires multifaceted data input parameters to describe
the various relations and probability distributions as shown in Table 2. Data was gathered from various literature studies
reporting on cases of norovirus based on quantitative risk assessment procedure. To improve on the results from limited data
described in the available literature studies, simulations were performed based on the available data using Markov Chain
Monte Carlo with hypercube sampling procedure for 100,000 iterations for each simulations. Computations were performed
in Matrix Laboratory (MatLab) (www.mathworks.com/) and in R (www.rproject.org/) and using the mc2d package (Pouillot
et al., 2015) with output designs carried out in Palisade Decision Suite (www.palisade.com/risk) and? @Risk built-in software
for Excel version 7.5.2. Input parameters for the modeling are as shown in Table 2.
4.1.1. Results on the modeling
The inclusion of temporary acquired immunity data for risk estimation gives a much lesser estimate of risk of illness
compared to the naïve approach currently in use, as indicated (Fig.1). Comparatively, using themedian risk of illness estimate,
the dose model has an approximately 1 log less estimate than the naïve model. The immunity model recorded 2 logs less to
the naïve model and a 1 log less to the dose model.
Moreover, by incorporating the disease immunity protection for the probability of illness given infection, the dose-
immunity model had 3 logs, 2 logs and 1 log of magnitude less to the naïve model, dose model and immunity model
respectively.
The impact measured by the inclusion of temporary acquired immunity shows a great difference in infection to illness
estimation. Assuming a ﬁxed dose of 1 norovirus particle, a constant daily exposure per annum and assigning a uniform
distribution for the loss of full and partial immunity, the result shows a decline on incidence of illness fromnaïve, dose-model,
immunity model and dose-immunity model, the immunity waning effect the total number that result in illness within the
population, the illness number level saw a sharp decline when immunity model is used instead of naïve model, and hence by
incorporating the effect of the dose dependent, the dose model and the dose-immunity model resulted in a further decline in
prediction of illness numbers (Fig. 2).Table 2
Input parameter values.
Parameter Description Estimate Estimate
Value(s)
Unit
Pinf Probability of infection Estimate from
equations
e
d Arithmetic Mean Dose per exposure per occasion Variable [1,1000]
[500.5]
e
mðaÞ Parametric Mean dose 1106 Teunis et al. (2008)
j The infection probability for subjects with
disaggregated dose
0.722 Messner et al. (2014)
A Life Expectancy 63
Pill Probability of illness Calculated Median
[5.40E-04]
e
Pilljinf probability of illness given infection Calculated Median
[1.08E-03]
e
N Assumed Population for simulation 2.50Eþ07 Population pyramids (2015)
E Total Exposure Uniform
distribution
[208,365]
[286.5]
(Mara, Hamilton, Sleigh, & Karavarsamis, 2010;
Seidu et al., 2008)
r;h Dose response parameters for illness given
infection
0.086, 2.60E-
03
Teunis et al. (2008)
a Loss of full immunity Uniform
distribution
[8,13] [10][ Simmons, Gambhir, Leon, and Lopman (2013)
g Loss of partial immunity Uniform
distribution
[3,6][5] Simmons et al. (2013)
l Force of infection Estimated from
equation
0.238165 e
t Inﬂation factor Estimated from
equation
0.793116 e
Fig. 1. Reduction of Risk of Illness per Person per year for Exposure.
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The various transmission scenarios of norovirus included in this study are as described below;
 Symptomatic Individual Infectious
Only symptomatic individuals are infectious. This comprises individuals in the population under the assumption that all
exposed individuals are susceptible to norovirus infection and none is genetically resistant. It is worth noting that the naïve
model dose do not relate to symptomatic individuals infectiousness. The earlier refers to estimation of risk without inclusion
of temporary acquired immunity.Fig. 2. Reduction of risk of illness for acquired immunity for population.
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Pre-symptomatic persons are individuals exposed but yet to be symptomatic of the infection (Ozawa et., 2007; Simmons
et al., 2013; Sukhrie et al., 2012; Sukhrie, Siebenga, Beersma, & Koopmans, 2010; Teunis et al., 2014).
 Pre-symptomatic and Post-symptomatic infectiousness (High)
In this scenario, individuals exposed and asymptomatic (Teunis et al., 2014).
 Innate Genetic Resistance
This is based on the assumption that part of the population is completely resistant to infection and disease, thus possessing
the non-secretor phenotype and therefore playing no role in transmission process. However, such individuals do make
contact with persons included in the empirical incidence estimate (Frenck et al., 2012). This is also different from immunity
model or dose-immunity models; the innate genetic resistance is the inclusion of individuals whose genetic make-up ex-
cludes them from infectiousness, yet forms part of the population.
 Scenario E: Genogroup 2 Type 4 (GII.4)
The previous four (4) transmission scenarios assume all norovirus to be anti-genetically indistinguishable. In this scenario,
it is assumed that only GII4 strains are infectious. The incidence of GII.4 is estimated based on values from (Huynen et al.,
2013; Nordgren, Kindberg, Lindgren, Matussek, & Svensson, 2010; Vega et al., 2011); (Frenck et al., 2012) (Simmons et al.,
2013).
 Scenario F: No Immune Boosting by Asymptomatic Infection
Persons do not travel from recovery of illness to direct asymptomatic individuals, the only pathway out of the recovery
from illness is through waning of full and partial immunity to become susceptible again.
Data input for modeling scenarios above are based on epidemiological studies shown in Table 3.
4.2.1. Results on the modeling
The Incidence of illness/infection models.
The transmission dynamics in all scenarios had probability of infection/illness incidence for dose-immunity model within
3.32108 e 7.11108, immunity model falls within 8.76106 e 1.12105, dose model falls within 1.19103 e
1.21103 and Naïve model falls within 1101 e 3.09101 (Table 4). A difference of 7 logs (median values) of magnitude
was found between the dose-immunity and the naïve model for all epidemiological transmission dynamics. Five and 3 logs
differences for dose-immunity as against the dose model and the immunity model, respectively. Hence, the probability of
infection/illness decreases from the naïve, the dose model, the immunity model and the dose-immunity model. The indi-
vidual infection/illness risk estimates for various immunity-incorporated models (dose-immunity, immunity) across the
transmission scenarios gave a much lesser risk incidence as compared to the naïve and the dose-model approaches (Figs.
3e8).
Transmission dynamics.
Across the different transmission dynamics scenarios with respect to their loss of partial and full temporary immunity
protection levels (Table 4), a comparison of models of the epidemiological scenarios using their median values did not show aTable 3
Norovirus epidemiological data for modeling.
Parameter Scenario A Scenario B Scenario C Scenario D Scenario E Scenario F
Loss of full immunity(aper year) 0.1 0.1 0.1 0.1 0.1 0.1
Loss of partial immunity (gper year) ð 104Þ 4.22e7.02 4.12e6.85 2.42e4.02 5.39e8.44 3.42e4.91 4.17e7.02
Duration of incubation ms (days) 1 1 1 1 1 1
Duration of asymptomatic infection r (days) 10 10 10 10 10 10
Duration of symptoms ma (days) 2 2 2 2 2 2
Relative infectiousness during asymptomatic infection period 0 0.05 0.25 0 0 0
Relative infectiousness during incubation period 0 0.05 0.25 0 0 0
Strains Included All All All All GII.4 All
Boosting of immunity by asymptomatic infection Yes Yes Yes Yes Yes No
Total Exposure for Annual quantiﬁcation (days) 1e365 1e365 1e365 1e365 1e365 1e365
Parameter values (Huynen et al., 2013; Simmons et al., 2013; Sukhrie et al., 2010, 2012; Tribble et al., 2010).
Table 4
Annual Individual risk of Illness for Dose-Response Models without Temporal Acquired Immunity.
Scenarios/Models Naïve Model Dose Model
Median Mean StDev Median Mean StDev
Symptomatic Individual Infectious 3.09 101 3.09 101 4.89 102 1.21 103 1.50 103 1.22 103
Pre-symptomatic and Post-symptomatic infectiousness (Low) 3.09 101 3.09 101 4.86 102 1.19 103 1.20 103 1.22 103
Pre-symptomatic and Post-symptomatic infectiousness (High) 3.09 101 3.09 101 4.89 102 1.20 103 1.50 103 1.21 103
Innate Genetic Resistance 3.09 101 3.09 101 4.89 102 1.21 103 1.49 103 1.21 103
Geno-group 2 Type 4 (GII.4) 3.09 101 3.09 101 4.89 102 1.19 103 1.49 103 1.21 103
No Immune Boosting by Asymptomatic Infection 3.09 101 3.09 101 4.89 102 1.21 103 1.50 103 1.22 103
Fig. 3. Reduction of risk of illness for ‘Symptomatic infectiousness’ of norovirus per Person per Year.
Fig. 4. Reduction of risk of illness for ‘Pre-Symptomatic and Post-Symptomatic infectiousness Low’ of norovirus per Person per Year.
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Fig. 5. Reduction of risk of illness for ‘Pre-Symptomatic and Post-Symptomatic infectiousness High’ of norovirus per Person per Year.
Fig. 6. Reduction of risk of illness for ‘Innate Genetic Resistance’ of norovirus per Person per Year.
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which had 1 log less for pre-symptomatic and post-symptomatic low. Therefore, difference in the probability of infection/
illness is not sensitive to the epidemiological transmission scenarios, thus, norovirus transmissions dynamics does not in-
ﬂuence the probability of infection/illness predictions (Table 5).
Furthermore, the ﬁndings observed no difference for all infection response models of the transmission dynamics for
symptomatic infectiousness' and the ‘no immune boosting after asymptomatic infectiousness’ (Tables 4 and 5). This conﬁrms
the study by Teunis et al. (2014) which indicates that shedding of virus is similar for both symptomatic and asymptomatic
infectiousness. However, it is worth noting that some differences were recorded studies for shedding of virus of infected
subjects (Atmar, Opekum, & Gilger, 2008). These differences are attributed to the genotype studied (Teunis et al., 2014).
Nevertheless, the difference in numbers shed could not have clinical signiﬁcance, hence such indifference in risk estimate of
illness as seen in this study is not unusual.
Fig. 7. Reduction of risk of illness for ‘Genogroup II Type 4’ of norovirus per Person per Year.
E.d.-G.J. Owusu-Ansah et al. / Infectious Disease Modelling 4 (2019) 99e114112Considering the ﬁndings under models without temporarily acquired immune inclusion (Table 4), both the median values
and mean values as well as their deviations were found to be the same for ‘pre-symptomatic and post e symptomatic (high)’
and ‘symptomatic infectiousness’ as well as recording similar estimates for ‘innate genetic resistance and geno-group 2 Type
4’ transmissions dynamics. This ﬁnding was not realized under any of the models or scenarios when acquired immunity is
incorporated in the modeling process.5. Conclusion
Applying the models to the norovirus data, resulted with the same trend of movement on the various dose-response
models, and individual level of illness incidence reduction was much better measured by immunity incorporated models.Fig. 8. Reduction of risk of illness for ‘No Immune Boosting after Asymptomatic Infection’ of norovirus per Person per Year.
Table 5
Annual risk of Illness for Dose-Response Models with Temporal Acquired Immunity.
Scenarios/Models Immunity Model Dose-Immunity Model
Median Mean StDev Median Mean StDev
Symptomatic Individual Infectious 1.51 105 3.96 105 5.92 105 5.77 108 5.92 108 1.31 108
Pre-symptomatic and Post-symptomatic infectiousness (Low) 1.47 105 3.85 105 5.75 105 5.65 108 5.78 108 1.27 108
Pre-symptomatic and Post-symptomatic infectiousness (High) 8.76 105 2.26 105 3.36 105 3.32 108 3.39 108 7.46 109
Innate Genetic Resistance 1.87 105 4.85 105 7.18 105 7.11 108 7.29 108 1.55 108
Genogroup 2 Type 4 (GII.4) 1.12 105 2.93 105 4.35 105 4.29 108 4.39 108 8.56 109
No Immune Boosting by Asymptomatic Infection 1.51 105 3.94 105 5.89 105 5.77 108 5.89 108 1.31 108
E.d.-G.J. Owusu-Ansah et al. / Infectious Disease Modelling 4 (2019) 99e114 113The immunity incorporated models tend to predict a lower illness/infection incidence, while the non-immunity incor-
porated models do not. Again, the immunity dependent models (immunity and dose-immunity models) meet the more
stringent WHO infection/illness threshold of 1:0 106 per person per exposure in all transmission scenarios.
The resulting magnitude of decrease in probability estimation of risk of illness is having a pronounced effect on the
estimation of diseases as a result of incorporation of the temporary immune dose response, irrespective of the scenario of
transmission of infected individuals, hence the results agree with Swart et al., 2012 and Havelaar & Swart, 2014.
These modeling results throw more light on the overestimation of the probable infection/illness as a result of the use of
naïve and dosemodels approach. It is important to note that the immunity model, which is a buildup of inclusion for immune
system response in the ﬁrst stage, is a better estimation in terms of predicting the reality of infection/illness of exposure than
the naïve approach. The lower estimates for the immunity-incorporated models indicates the impacts of the temporary
immune response to offer full protection and always results in lower estimates as compared to the naïve estimates (Tribble
et al., 2010). It is also important to note that the dynamics of the norovirus transfer from person to person does not inﬂuence
the responses of the models, hence the prediction models superimpose on the type of the transmission of the virus.
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